gauthier_therapy

05 vs placebo placebo reminyl 16 mgd reminyl 24 mgd

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: 4 5 6 0 1 3 5 Deterioration Months *P < 0.05 vs placebo. Placebo Reminyl® 16 mg/d Reminyl® 24 mg/d © TND 2005 LS mean change from baseline ± SE Behavior: Neuropsychiatric Inventory (NPI) Behavior: 12-item total 12-item -8 p=0.0083 -6 p=0.0005 p=0.0618 p=0.0303 -4 Clinical improvement -2 Baseline 0 2 4 Donepezil Clinical decline Placebo 0 4 8 12 18 Donepezil n=138 130 114 Study week 124 118 Placebo n=144 116 128 138 128 24 ITT LOCF 119 (138) 125 (144) © TND 2005 GLOBAL OUTCOMES Clinical Global Impression of Change (CGIC) Clinical Interview Based Impression of Change (CIBIC) with caregiver input (CIBIC+) Clinical Dementia Rating (CDR) © TND 2005 CHOLINESTERASE INHIBITORS FOR AD: CHOLINESTERASE RECOMMENDATIONS RECOMMENDATIONS Patients in mild to moderately severe stages of AD should be offered a trial of a CI of at least 6 months. Baseline and follow­up assessments should include mood, cognition, functional autonomy and behavior. Continue if improvement or stabilization of symptoms. © TND 2005 ISSUES IN CLINICAL PRACTICE: ISSUES CLINICAL ASSESSMENT OF RESPONSE TO CI TO Global...
View Full Document

This document was uploaded on 03/07/2014 for the course BIOLOGY BIO at NYU.

Ask a homework question - tutors are online